Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EBIT (2016 - 2026)

Apyx Medical filings provide 15 years of EBIT readings, the most recent being $11000.0 for Q4 2025.

  • On a quarterly basis, EBIT rose 100.36% to $11000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.4 million, a 65.79% increase, with the full-year FY2025 number at -$6.4 million, up 65.79% from a year prior.
  • EBIT hit $11000.0 in Q4 2025 for Apyx Medical, up from -$832000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $11000.0 in Q4 2025 to a low of -$6.6 million in Q1 2024.
  • Median EBIT over the past 5 years was -$4.3 million (2021), compared with a mean of -$4.0 million.
  • Biggest five-year swings in EBIT: tumbled 349.15% in 2024 and later soared 100.36% in 2025.
  • Apyx Medical's EBIT stood at -$1.7 million in 2021, then tumbled by 250.65% to -$5.9 million in 2022, then grew by 2.65% to -$5.8 million in 2023, then soared by 47.23% to -$3.0 million in 2024, then soared by 100.36% to $11000.0 in 2025.
  • The last three reported values for EBIT were $11000.0 (Q4 2025), -$832000.0 (Q3 2025), and -$2.6 million (Q2 2025) per Business Quant data.